Project Grant HT94252310302
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
El Macero, CA 95618, USA
Similar Awards
The University of California, Davis was awarded a $1,446,009 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to target CD200/CD200R signaling as a novel strategy for treating therapy-resistant prostate cancer. The grant, awarded July 1, 2023 and set to be completed by June 30, 2026, will support research into medical solutions for prostate cancer that remains unresponsive to standard treatments by...
The University of California, Davis was awarded a $1,177,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research to target a key tumor plasticity driver in lethal prostate cancer. Through August 2021 to July 2024, UC Davis researchers will investigate medical solutions for prostate cancer on the cellular level with the aim of transforming patient care and outcomes. The...
The University of California, Davis received a $1,801,179 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on April 15, 2025, supports advanced biomedical research to investigate the contribution of bone mass and fracture to bone metastasis in prostate cancer. As a prominent research university, UC Davis leverages its extensive scientific expertise and research...
This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
This Project Grant award of $636,285 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Davis (UC Davis) on "TRIPLE AKR1C3/COX2/SEH INHIBITION FOR THE TREATMENT OF LETHAL PROSTATE CANCER." The funding will be used over a 3-year period from September 2023 to August 2026 to conduct basic, translational, and clinical research aimed at developing new treatments for prostate cancer, a key health...
This federal Project Grant award, totaling $1,163,420.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Davis. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research aims to investigate functional and phenotypic metabolic transitions governing disease state in clear cell renal cell...
The University of California, Davis (UC Davis) has been awarded a $644,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on June 1, 2025, will support research focused on "PLZ4-TARGETING ULTRA-SMALL DM1 NANOCONJUGATE FOR BLADDER CANCER THERAPY" with a completion date of May 31, 2027. As a prominent public research university, UC Davis has extensive expertise in...
The University of California, Davis was awarded a $483,000 Project Grant from the Department of the Army's Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING DRUG-TOLERANT PERSISTER CELLS IN OVARIAN CANCER." The award period is from April 1, 2024 to March 31, 2026. The objective of this research project is to develop new treatments for ovarian cancer by targeting drug-tolerant persister cells. As a major public research university, UC...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, in the amount of $442,750.00, supports research to determine the role of histone lactylation in post-traumatic osteoarthritis and arthritic pain. The award was made to the University of California, Davis, a prominent public research university with extensive expertise in medical research, on February 1, 2025, with a planned completion date of January 31,...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...